College of Veterinary Medicine, University of Florida, Gainesville, Florida.
College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
J Vet Intern Med. 2020 Mar;34(2):600-606. doi: 10.1111/jvim.15746. Epub 2020 Feb 29.
An angiotensin-converting enzyme (ACE) gene polymorphism occurs in dogs; however, functional importance is not well studied.
We hypothesized that dogs with the polymorphism would show alternative renin-angiotensin aldosterone system (RAAS) pathway activation and classical RAAS pathway suppression before and after ACE-inhibitor administration, as compared to dogs without the polymorphism that would show this pattern only after ACE-inhibitor administration.
Twenty-one dogs with mitral valve disease that were genotyped for the ACE gene polymorphism.
This retrospective study utilized stored samples from 8 ACE gene polymorphism-negative (PN) dogs and 13 ACE gene polymorphism-positive (PP) dogs before and after enalapril administration. Equilibrium analysis was performed to evaluate serum RAAS metabolites and enzyme activities. Results were compared before and after enalapril, and between groups.
The classical RAAS pathway was suppressed and the alternative RAAS pathway was enhanced for both genotypes after administration of enalapril, with no differences before enalapril administration. Aldosterone breakthrough occurred in both PN (38%) and PP (54%) dogs despite angiotensin II suppression. Aldosterone was significantly higher (P = .02) in ACE gene PP dogs (median, 92.17 pM; IQR, 21.85-184.70) compared to ACE gene PN dogs (median, 15.91 pM; IQR, <15.00-33.92) after enalapril.
The ACE gene polymorphism did not alter baseline RAAS activity. Aldosterone breatkthrough in some dogs suggests nonangiotensin mediated aldosterone production that might be negatively influenced by genotype. These results support the use of aldosterone receptor antagonists with ACE-inhibitors when RAAS inhibition is indicated for dogs, especially those positive for the ACE gene polymorphism.
犬体内存在血管紧张素转换酶(ACE)基因多态性,但该多态性的功能意义尚未得到充分研究。
我们假设与没有该多态性的犬相比,携带该多态性的犬在接受 ACE 抑制剂治疗前后会表现出不同的肾素-血管紧张素-醛固酮系统(RAAS)途径激活和经典 RAAS 途径抑制,而没有该多态性的犬只有在接受 ACE 抑制剂治疗后才会出现这种模式。
21 只患有二尖瓣疾病的犬,对 ACE 基因多态性进行了基因分型。
本回顾性研究利用了 8 只 ACE 基因多态性阴性(PN)犬和 13 只 ACE 基因多态性阳性(PP)犬在接受依那普利治疗前后的储存样本。进行平衡分析以评估血清 RAAS 代谢物和酶活性。比较了治疗前后和组间的结果。
在接受依那普利治疗后,两种基因型的经典 RAAS 途径均受到抑制,替代 RAAS 途径均增强,而在接受依那普利治疗前则没有差异。尽管血管紧张素 II 受到抑制,但在 PN(38%)和 PP(54%)犬中均发生了醛固酮突破。与 ACE 基因 PN 犬(中位数,15.91 pM;IQR,<15.00-33.92)相比,ACE 基因 PP 犬(中位数,92.17 pM;IQR,21.85-184.70)在接受依那普利治疗后,醛固酮显著升高(P=0.02)。
ACE 基因多态性并未改变基线 RAAS 活性。一些犬中出现的醛固酮突破表明存在非血管紧张素介导的醛固酮生成,其可能受基因型的负性影响。这些结果支持在 RAAS 抑制适用于犬时,尤其是 ACE 基因多态性阳性的犬,使用醛固酮受体拮抗剂与 ACE 抑制剂联合治疗。